Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Biopub

<< Previous

Bullboard Posts

Next >>

Post by Ogre03on Dec 09, 2020 1:53pm

290 Views

Post# 32068926

Biopub

rather enjoyed that "fire side" chat. Couple of points gleaned . 352 human trials end of 2020 hopefully. Bench offering not on the table in the near future. Partnership over sale preferred Toxicity trials completed early q1 Little less stress for me now anyway now on this front

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale